Overview

• Researchers at University College London led a decade-long study involving 500 patients from five countries.
• The new regimen involves a short course of chemotherapy before the standard chemoradiation treatment.
• Results show a 40% reduction in death risk and a 35% decrease in cancer recurrence within five years.
• The treatment uses existing, affordable drugs and can be quickly implemented globally.
• Experts urge the widespread adoption of this regimen, highlighting its potential to significantly improve survival rates.